$165 Million is the total value of Stonepine Capital Management, LLC's 25 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 90.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BSTC | Sell | BIOSPECIFICS TECHNOLOGIES | $20,695,000 | -20.9% | 461,315 | -21.8% | 12.58% | -10.3% |
| CTIC | Sell | CTI BIOPHARMA CORP | $20,166,000 | +0.6% | 4,049,298 | -21.2% | 12.25% | +14.0% |
| APEN | APOLLO ENDOSURGERY INC | $17,994,000 | +11.4% | 2,577,996 | 0.0% | 10.93% | +26.3% | |
| AMRN | Sell | AMARIN CORP PLC -ADRspons adr new | $17,521,000 | +1.0% | 5,670,205 | -1.6% | 10.65% | +14.6% |
| VNDA | Sell | VANDA PHARMACEUTICALS INC | $11,430,000 | -31.1% | 600,000 | -39.1% | 6.94% | -21.9% |
| VIVE | VIVEVE MEDICAL INC | $10,471,000 | -25.7% | 3,849,711 | 0.0% | 6.36% | -15.7% | |
| CPIX | Sell | CUMBERLAND PHARMACEUTICALS | $7,376,000 | -16.5% | 1,203,339 | -9.0% | 4.48% | -5.4% |
| CORV | New | CORREVIO PHARMA CORP | $7,295,000 | – | 1,930,022 | +100.0% | 4.43% | – |
| ALIM | Buy | ALIMERA SCIENCES INC | $6,830,000 | +7.3% | 6,981,184 | +13.0% | 4.15% | +21.7% |
| NVLNF | Sell | NOVELION THERAPEUTICS INC | $6,598,000 | +1.4% | 1,792,911 | -3.6% | 4.01% | +14.9% |
| HTGM | New | HTG MOLECULAR DIAGNOSTICS | $5,506,000 | – | 1,689,064 | +100.0% | 3.35% | – |
| OPHT | Buy | OPHTHOTECH CORP | $5,220,000 | +19.6% | 1,912,018 | +20.0% | 3.17% | +35.6% |
| BDSI | Sell | BIODELIVERY SCIENCES INTL | $4,384,000 | -47.4% | 1,486,002 | -59.9% | 2.66% | -40.4% |
| RIGL | New | RIGEL PHARMACEUTICALS INC | $4,235,000 | – | 1,496,590 | +100.0% | 2.57% | – |
| ADMA | New | ADMA BIOLOGICS INC | $3,751,000 | – | 831,731 | +100.0% | 2.28% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $2,976,000 | – | 194,900 | +100.0% | 1.81% | – |
| ATEC | New | ALPHATEC HOLDINGS INC | $2,692,000 | – | 903,224 | +100.0% | 1.64% | – |
| CATB | New | CATABASIS PHARMACEUTICALS IN | $2,302,000 | – | 2,400,000 | +100.0% | 1.40% | – |
| CDTX | New | CIDARA THERAPEUTICS INC | $2,213,000 | – | 425,531 | +100.0% | 1.34% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $1,393,000 | – | 198,373 | +100.0% | 0.85% | – |
| CGIX | Sell | CANCER GENETICS INC | $1,239,000 | -57.6% | 1,391,607 | -21.5% | 0.75% | -51.9% |
| GEMP | Sell | GEMPHIRE THERAPEUTICS INC | $1,050,000 | -33.6% | 103,000 | -57.6% | 0.64% | -24.7% |
| CFMS | Sell | CONFORMIS INC | $770,000 | -80.9% | 616,109 | -77.8% | 0.47% | -78.3% |
| MLNT | New | MELINTA THERAPEUTICS INC | $331,000 | – | 52,200 | +100.0% | 0.20% | – |
| NVIV | New | INVIVO THERAPEUTICS HOLDINGS | $132,000 | – | 77,900 | +100.0% | 0.08% | – |
| AQXP | Exit | AQUINOX PHARMACEUTICALS INC | $0 | – | -20,374 | -100.0% | -0.15% | – |
| EYEN | Exit | EYENOVIA INC | $0 | – | -39,902 | -100.0% | -0.20% | – |
| SCYX | Exit | SCYNEXIS INC | $0 | – | -380,083 | -100.0% | -0.27% | – |
| IMDZ | Exit | IMMUNE DESIGN CORP | $0 | – | -161,226 | -100.0% | -0.28% | – |
| EOLS | Exit | EVOLUS INC | $0 | – | -59,229 | -100.0% | -0.29% | – |
| FOMX | Exit | FOAMIX PHARMACEUTICALS LTD | $0 | – | -129,756 | -100.0% | -0.36% | – |
| ZSAN | Exit | ZOSANO PHARMA CORP | $0 | – | -200,000 | -100.0% | -0.54% | – |
| NVTA | Exit | INVITAE CORP | $0 | – | -219,022 | -100.0% | -0.55% | – |
| SRRA | Exit | SIERRA ONCOLOGY INC | $0 | – | -570,987 | -100.0% | -0.63% | – |
| IVTY | Exit | INVUITY INC | $0 | – | -507,028 | -100.0% | -1.05% | – |
| STDY | Exit | STEADYMED LTD | $0 | – | -721,308 | -100.0% | -1.26% | – |
| Exit | MEDICREA INTERNATIONAL | $0 | – | -714,729 | -100.0% | -1.49% | – | |
| OXFD | Exit | OXFORD IMMUNOTEC GLOBAL PLC | $0 | – | -263,974 | -100.0% | -1.76% | – |
| VCYT | Exit | VERACYTE INC | $0 | – | -773,889 | -100.0% | -2.31% | – |
| DOVA | Exit | DOVA PHARMACEUTICALS INC | $0 | – | -184,000 | -100.0% | -2.67% | – |
| CRME | Exit | CARDIOME PHARMA CORP | $0 | – | -3,241,550 | -100.0% | -4.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.